Synthetic Peptide Solutions That Keep Your Program Moving

The peptide industry is undergoing significant and sustained growth as peptide-based therapeutics gain increasing acceptance across a wide range of clinical and commercial applications. This expanding therapeutic footprint is driving heightened demand for robust, scalable, and regulatory-compliant manufacturing solutions capable of supporting late-stage development and commercial supply. In response to recent requirements for multi-ton (MT) production volumes, manufacturers are re-evaluating traditional solid-phase peptide synthesis (SPPS) approaches and adopting hybrid SPPS/liquid-phase peptide synthesis (LPPS) strategies. These integrated workflows typically employ SPPS or LPPS for efficient fragment generation, followed by LPPS to assemble those fragments into the final active pharmaceutical ingredient (API) at scale. At SK pharmteco, our team applies deep expertise in small-molecule manufacturing, combined with targeted investments in technology, infrastructure, and process development, to overcome the technical and operational challenges associated with large-scale peptide production and to support our partners throughout the product lifecycle.